JP2023533447A - がんを処置する併用療法 - Google Patents

がんを処置する併用療法 Download PDF

Info

Publication number
JP2023533447A
JP2023533447A JP2022578991A JP2022578991A JP2023533447A JP 2023533447 A JP2023533447 A JP 2023533447A JP 2022578991 A JP2022578991 A JP 2022578991A JP 2022578991 A JP2022578991 A JP 2022578991A JP 2023533447 A JP2023533447 A JP 2023533447A
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
alkyl
group
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022578991A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023533447A5 (https=
Inventor
アーノルド レビン，
メリッサ ダンブル，
Original Assignee
ピーエムブイ ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ピーエムブイ ファーマシューティカルズ， インコーポレイテッド filed Critical ピーエムブイ ファーマシューティカルズ， インコーポレイテッド
Publication of JP2023533447A publication Critical patent/JP2023533447A/ja
Publication of JP2023533447A5 publication Critical patent/JP2023533447A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2022578991A 2020-06-24 2021-06-15 がんを処置する併用療法 Pending JP2023533447A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063043342P 2020-06-24 2020-06-24
US63/043,342 2020-06-24
US202163162184P 2021-03-17 2021-03-17
US63/162,184 2021-03-17
PCT/US2021/037473 WO2021262484A1 (en) 2020-06-24 2021-06-15 Combination therapy for treatment of cancer

Publications (2)

Publication Number Publication Date
JP2023533447A true JP2023533447A (ja) 2023-08-03
JP2023533447A5 JP2023533447A5 (https=) 2024-06-25

Family

ID=79281702

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022578991A Pending JP2023533447A (ja) 2020-06-24 2021-06-15 がんを処置する併用療法

Country Status (10)

Country Link
US (2) US11938124B2 (https=)
EP (1) EP4171548A4 (https=)
JP (1) JP2023533447A (https=)
KR (1) KR20230028484A (https=)
CN (1) CN116096704A (https=)
AU (1) AU2021297716A1 (https=)
CA (1) CA3183081A1 (https=)
IL (1) IL298592A (https=)
MX (1) MX2022015793A (https=)
WO (1) WO2021262484A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12570645B2 (en) 2020-06-22 2026-03-10 Pmv Pharmaceuticals, Inc. Uses of p53 x-ray co-crystal structures
CA3183025A1 (en) * 2020-06-24 2021-12-30 Melissa Dumble Companion diagnostic tool for mutant p53 reactivating compounds
WO2022213975A1 (en) * 2021-04-08 2022-10-13 Jacobio Pharmaceuticals Co., Ltd. Compounds targeting y220c mutant of p53
UY39890A (es) * 2021-08-10 2023-03-31 Jacobio Pharmaceuticals Co Ltd Compuestos con diana en mutante de p53
WO2023025324A1 (zh) * 2021-08-27 2023-03-02 杭州紫晶医药科技有限公司 作为p53调节剂的化合物
AU2023213949A1 (en) 2022-01-27 2024-07-25 Pmv Pharmaceuticals, Inc. Deuterated compounds for restoring mutant p53 function
WO2023225477A2 (en) * 2022-05-16 2023-11-23 Pmv Pharmaceuticals, Inc. Methods and compounds for restoring mutant p53 function
WO2024017384A1 (zh) * 2022-07-22 2024-01-25 深圳众格生物科技有限公司 恢复p53突变功能的化合物及其应用
CN119968361A (zh) * 2022-08-22 2025-05-09 北京加科思新药研发有限公司 靶向p53 Y220突变体的化合物
WO2024086804A1 (en) * 2022-10-21 2024-04-25 Scorpion Therapeutics, Inc. Indolizine derivatives for treating cancer
TW202435861A (zh) * 2022-12-08 2024-09-16 大陸商北京加科思新藥研發有限公司 靶向p53突變體的化合物
TW202515872A (zh) * 2023-06-27 2025-04-16 大陸商長春金賽藥業有限責任公司 ｐ５３－Ｙ２２０Ｃ選擇性小分子重啟動劑化合物、藥物組合物及其用途
CN121693500A (zh) * 2023-08-09 2026-03-17 德睿智药(苏州)新药研发有限公司 用于调节p53功能的新型杂环类化合物
WO2025011684A2 (zh) * 2023-10-20 2025-01-16 上海宇道生物技术有限公司 一类n-磺酰酰胺含氮稠杂环类化合物及其应用
WO2026067649A1 (zh) * 2024-09-27 2026-04-02 奇树医药公司 恢复p53突变功能的化合物及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019512465A (ja) * 2016-02-19 2019-05-16 ピーエムブイ ファーマシューティカルズ， インコーポレイテッド 変異体ｐ５３機能を復元させるための方法および化合物

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4302589A (en) * 1980-05-08 1981-11-24 American Cyanamid Company Cis-mono and disubstituted-2-methyl-3-[(piperazinyl) and (piperidino)ethyl]indolines, intermediates for their preparation and methods of preparation
CN1329493A (zh) 1998-12-02 2002-01-02 辉瑞产品公司 恢复p53家族蛋白质的构象稳定性的方法和组合物
US6770652B2 (en) 2001-10-18 2004-08-03 Duquesne University Of The Holy Ghost Multiple acting anti-angiogenic and cytotoxic compounds and methods for using the same
CA2511625A1 (en) * 2002-12-23 2004-07-15 City Of Hope Modified vaccinia ankara expressing p53 in cancer immunotherapy
JP2008505910A (ja) 2004-07-08 2008-02-28 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド Ｐｋｃ−シータのインヒビターとして有用なピリミジン誘導体
WO2006136823A1 (en) 2005-06-21 2006-12-28 Astex Therapeutics Limited Heterocyclic containing amines as kinase b inhibitors
US8822420B2 (en) 2008-03-13 2014-09-02 Universita Degli Studi Di Trieste Peptides and aptamers thereof as specific modulators of mutant p53 function
GB0808282D0 (en) 2008-05-07 2008-06-11 Medical Res Council Compounds for use in stabilizing p53 mutants
AU2009322774A1 (en) 2008-12-03 2011-06-30 Via Pharmaceuticals, Inc Inhibitors of diacylglycerol acyltransferase
DK2410844T3 (en) 2009-03-27 2016-07-04 Merck Sharp & Dohme Inhibitors of hepatitis C virus replication
DE102010049877A1 (de) 2010-11-01 2012-05-03 Merck Patent Gmbh 7-((1,2,3)Triazol-4-yl)-pyrrolo(2,3) pyrazinderivate
RU2598842C2 (ru) 2011-01-20 2016-09-27 Мерк Шарп Энд Домэ Корп. Антагонисты рецептора минералокортикоидов
GB201110390D0 (en) 2011-06-20 2011-08-03 Medical Res Council Compounds for use in stabilising p53 mutants
US9517252B2 (en) 2011-09-09 2016-12-13 Agency For Science, Technology And Research p53 activating peptides
EP2809656A2 (en) 2011-12-28 2014-12-10 Allergan, Inc. Benzimidazole derivatives as selective blockers of persistent sodium current
US8822689B2 (en) 2012-09-19 2014-09-02 Merial Limited Aryloazol-2-yl cyanoethylamino compounds, method of making and method of using thereof
WO2015089187A1 (en) * 2013-12-10 2015-06-18 Incuron, Llc Methods of modulating various biomarkers with curaxins
EP3145512B1 (en) 2014-05-19 2019-07-17 Jiangsu Hengrui Medicine Co., Ltd. Substituted ethynyl heterobicyclic compounds as tyrosine kinase inhibitors
US20170184604A1 (en) 2014-05-22 2017-06-29 The General Hospital Corporation Dd1alpha receptor and uses thereof in immune disorders
WO2016004513A1 (en) 2014-07-11 2016-01-14 Simon Fraser University Anti-bacterial pyruvate kinase modulator compounds, compositions, uses and methods
CN104672241B (zh) 2015-01-29 2018-04-24 王磊 吡咯并[2,3-d]嘧啶类化合物及其用途
EP3328418A1 (en) 2015-07-29 2018-06-06 Novartis AG Combination therapies comprising antibody molecules to pd-1
US20170114098A1 (en) 2015-09-03 2017-04-27 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
WO2017079746A2 (en) * 2015-11-07 2017-05-11 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
US10870640B2 (en) * 2016-04-08 2020-12-22 Institute For Cancer Research Prodigiosin analogs and methods of use
US20180008688A1 (en) * 2016-07-06 2018-01-11 Augusta University Research Institute, Inc. Method and compositions for enhancing immunotherapeutic treatment of a cancer
EP3528816A4 (en) 2016-10-21 2020-04-08 Nimbus Lakshmi, Inc. TYK2 INHIBITORS AND USES THEREOF
JP7103342B2 (ja) * 2017-03-23 2022-07-20 日本電産トーソク株式会社 ポンプ装置
US20200071326A1 (en) 2017-04-14 2020-03-05 Syros Pharmaceuticals, Inc. Tam kinase inhibitors
US20190002460A1 (en) 2017-06-28 2019-01-03 The Regents Of The University Of Michigan Small molecule inhibitors of egfr and pi3k
KR102577241B1 (ko) 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체
US11203598B2 (en) * 2018-01-24 2021-12-21 Institute For Cancer Research Compounds for repressing cancer cell growth
WO2019165576A1 (en) 2018-02-27 2019-09-06 President And Fellows Of Harvard College Methods for treating cancer and protecting renewable tissues
KR20210062044A (ko) * 2018-09-20 2021-05-28 아프레아 테라퓨틱스 에이비 퀴누클리딘-3-온 유도체와 암 치료에서 이의 용도
US12274784B2 (en) * 2018-10-12 2025-04-15 Synergene Therapeutics, Inc. Methods for reducing side effects of immunotherapy
US20220184087A1 (en) * 2019-03-28 2022-06-16 The Penn State Research Foundation Methods and compositions relating to treatment of cancer
EP4031136A1 (en) 2019-09-18 2022-07-27 Aprea Therapeutics AB Combination treatment with a p53 reactivator and an inhibitor of an antiapoptotic bcl-2 family protein
DK4034104T3 (da) 2019-09-23 2025-10-06 Pmv Pharmaceuticals Inc Metoder og forbindelser til genoprettelse af mutant p53-funktion
WO2021087096A1 (en) 2019-11-01 2021-05-06 The Regents Of The University Of California P53 modulators and uses thereof
TW202128156A (zh) 2019-11-14 2021-08-01 美商夸格智財控股有限公司 用於癌症治療之btk抑制劑及mdm2抑制劑之組合
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
WO2021170772A1 (en) 2020-02-26 2021-09-02 Aprea Therapeutics Ab Combination treatment with a p53 reactivator and an inhibitor of cd47 mediated signaling
WO2021207598A1 (en) 2020-04-10 2021-10-14 Aprea Therapeutics, Inc. Combination treatment with an agonist of p53 and a second therapeutic agent
WO2021231474A1 (en) * 2020-05-12 2021-11-18 Pmv Pharmaceuticals, Inc. METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION
US12570645B2 (en) 2020-06-22 2026-03-10 Pmv Pharmaceuticals, Inc. Uses of p53 x-ray co-crystal structures
CA3183025A1 (en) 2020-06-24 2021-12-30 Melissa Dumble Companion diagnostic tool for mutant p53 reactivating compounds
US20230049952A1 (en) 2020-06-24 2023-02-16 Pmv Pharmaceuticals, Inc. Methods and compounds for restoring mutant p53 function

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019512465A (ja) * 2016-02-19 2019-05-16 ピーエムブイ ファーマシューティカルズ， インコーポレイテッド 変異体ｐ５３機能を復元させるための方法および化合物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CANCER TREATMENT REVIEWS, vol. 63, JPN6025016077, 2018, pages 122 - 134, ISSN: 0005667962 *
GYNECOLOGIC ONCOLOGY RESEARCH AND PRACTICE, vol. Vol.3:11, JPN6025016078, 2016, pages 1 - 14, ISSN: 0005667963 *
JOURNAL OF CANCER, vol. 9, no. 10, JPN6025016076, 2018, pages 1773 - 1781, ISSN: 0005667961 *

Also Published As

Publication number Publication date
IL298592A (en) 2023-01-01
CA3183081A1 (en) 2021-12-30
CN116096704A (zh) 2023-05-09
US20240269126A1 (en) 2024-08-15
EP4171548A1 (en) 2023-05-03
MX2022015793A (es) 2023-02-27
EP4171548A4 (en) 2024-06-19
WO2021262484A1 (en) 2021-12-30
AU2021297716A1 (en) 2023-01-19
US20230033324A1 (en) 2023-02-02
US11938124B2 (en) 2024-03-26
KR20230028484A (ko) 2023-02-28

Similar Documents

Publication Publication Date Title
JP2023533447A (ja) がんを処置する併用療法
US6512002B2 (en) Methods of treatment for premature ejaculation in a male
US8669257B2 (en) Phenazine derivatives and uses thereof as potassium channel modulators
US20110033458A1 (en) Combinations comprising epothilones and pharmaceutical uses thereof
JPWO2003043655A1 (ja) 頻尿の治療剤
CN115968289B (zh) 用于治疗贫血的alk2抑制剂
TW201127384A (en) Therapeutic combination comprising a Cdc7 inhibitor and an antineoplastic agent
CN118401241A (zh) 用于治疗慢性肾脏病的醛固酮合成酶抑制剂
WO2021216814A1 (en) Btk inhibitors to treat pulmonary distress in covid-19 patients
JP2020500183A (ja) 肺高血圧症の治療のための併用療法
US20240374600A1 (en) Methods and compositions for treating cancer
MXPA06013902A (es) Procedimiento para tratar el crecimiento de celulas anormal.
JP2024540529A (ja) がんを処置するための方法および組成物
HK40091747A (zh) 用於治疗癌症的组合疗法
WO2021048419A1 (en) Combination therapies comprising trametinib for the treatment of cholangiocarcinoma
WO2025059081A1 (en) Bicyclic compounds for restoring mutant p53 function
MXPA06015148A (es) Combinacion que comprende un inhibidor de bcrp y 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il) pirimidin-2-ilamino)fenil]-benzamida.
WO2025202971A1 (en) Kras g12c inhibitor for use for the treatment of non-small cell lung cancer
CA3152840A1 (en) Use of an mdm2 inhibitor for the treatment of myelofibrosis
HK1141234A (en) Combinations comprising epothilones and pharmaceutical uses thereof
NZ537040A (en) Treating a proliferative disease comprising administering to the animal a combination that comprises (a) a HER-1 or a HER-2 antibody or (b) at least one antineoplastic agent
KR20050019125A (ko) 에포틸론을 포함하는 조합물 및 그의 제약적 용도

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240617

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240617

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250820

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251119

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260220